Fulcrum Therapeutics, Inc. (FULC)
3.51
-0.01
(-0.28%)
USD |
NASDAQ |
Jun 10, 16:00
3.51
0.00 (0.00%)
Pre-Market: 08:40
Fulcrum Therapeutics Enterprise Value : -93.65M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | -93.65M |
| June 09, 2026 | -92.99M |
| June 08, 2026 | -98.32M |
| June 05, 2026 | -81.67M |
| June 04, 2026 | -102.98M |
| June 03, 2026 | -112.97M |
| June 02, 2026 | -118.30M |
| June 01, 2026 | 100.18M |
| May 29, 2026 | 133.48M |
| May 28, 2026 | 126.82M |
| May 27, 2026 | 124.32M |
| May 26, 2026 | 122.99M |
| May 22, 2026 | 110.33M |
| May 21, 2026 | 111.66M |
| May 20, 2026 | 95.67M |
| May 19, 2026 | 66.35M |
| May 18, 2026 | 78.35M |
| May 15, 2026 | 118.33M |
| May 14, 2026 | 146.31M |
| May 13, 2026 | 155.64M |
| May 12, 2026 | 136.32M |
| May 11, 2026 | 138.98M |
| May 08, 2026 | 139.65M |
| May 07, 2026 | 130.99M |
| May 06, 2026 | 146.31M |
| Date | Value |
|---|---|
| May 05, 2026 | 140.32M |
| May 04, 2026 | 140.32M |
| May 01, 2026 | 162.97M |
| April 30, 2026 | 147.65M |
| April 29, 2026 | 148.98M |
| April 28, 2026 | 168.30M |
| April 27, 2026 | 186.96M |
| April 24, 2026 | 194.96M |
| April 23, 2026 | 210.95M |
| April 22, 2026 | 188.96M |
| April 21, 2026 | 174.30M |
| April 20, 2026 | 201.62M |
| April 17, 2026 | 224.73M |
| April 16, 2026 | 204.75M |
| April 15, 2026 | 222.07M |
| April 14, 2026 | 198.76M |
| April 13, 2026 | 187.43M |
| April 10, 2026 | 175.44M |
| April 09, 2026 | 199.42M |
| April 08, 2026 | 198.76M |
| April 07, 2026 | 194.09M |
| April 06, 2026 | 194.09M |
| April 02, 2026 | 208.08M |
| April 01, 2026 | 170.78M |
| March 31, 2026 | 183.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 10.45M |
| CNBX Pharmaceuticals, Inc. | 1.322M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -156.09M |
| Definium Therapeutics, Inc. | 2.085B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.89M |
| Total Expenses (Quarterly) | 18.89M |
| EPS Diluted (Quarterly) | -0.2479 |
| Earnings Yield | -32.66% |
| Normalized Earnings Yield | -32.67 |